The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“OPB-51602 has an anti-tumor effect in non-small-cell lung cancer but causes peripheral nerve disorders”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Wong et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Function of Mitochondrial Stat3 in Cellular Respiration
Wegrzyn, J., Potla, R., Chwae, Y.-J., Sepuri, N. B. V., Zhang, Q., Koeck, T., Derecka, M., Szczepanek, K., Szelag, M., Gornicka, A., et al. (2009) · Science · doi:10.1126/science.1164551 · Cited by 1,014
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555
Flagged first, then by citations
Research works printed but not linked: 10
- Yu, 2004, The STATs of cancer—new molecular targets come of age, Nat Rev Cancer, 4, 97, 10.1038/nrc1275 · DOI · Paper page
- Yu, 2007, Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment, Nat Rev Immunol, 7, 41, 10.1038/nri1995 · DOI
- Alvarez, 2006, Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor, Cancer Res, 66, 3162, 10.1158/0008-5472.CAN-05-3757 · DOI
- Yue, 2009, Targeting STAT3 in cancer: how successful are we?, Expert Opin Investig Drugs, 18, 45, 10.1517/13543780802565791 · DOI
- Genini, 2014, Novel inhibitors of signal transducer and activator of transcription 3 (STAT3) show potent activity in cell cultures and tumor xenografts, Can Res, 74, 953, 10.1158/1538-7445.AM2014-953 · DOI
- Young, 1999, Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group, Eur J Cancer, 35, 1773, 10.1016/S0959-8049(99)00229-4 · DOI
- Zhou, 2011, Mitochondrial localized STAT3 is involved in NGF induced neurite outgrowth, PLoS ONE, 6, e21680, 10.1371/journal.pone.0021680 · DOI
- van Vollenhoven, 2012, Tofacitinib or adalimumab versus placebo in rheumatoid arthritis, N Engl J Med, 367, 508, 10.1056/NEJMoa1112072 · DOI
- Koskela, 2012, Somatic STAT3 mutations in large granular lymphocytic leukemia, N Engl J Med, 366, 1905, 10.1056/NEJMoa1114885 · DOI
- Bendell, 2014, Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors, Cancer Chemother Pharmacol, 74, 125, 10.1007/s00280-014-2480-2 · DOI · Paper page
Cited by
Sorted by citations
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5272 · Cited by 445
Self-citationBharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“Further exploration of less frequent dosing in a subsequent trial for patients with refractory solid malignancies was suggested (Ogura et al., 2015; Wong et al., 2015).”
BackgroundThe STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations
Geiger, J. L., Grandis, J. R., & Bauman, J. E. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.022 · Cited by 193
Genini, D., Brambilla, L., Laurini, E., Merulla, J., Civenni, G., Pandit, S., D'Antuono, R., Perez, L., Levy, D. E., Pricl, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615730114 · Cited by 106
Metadata
- Authors
- Wong, A. L., Soo, R. A., Tan, D. S., Lee, S. C., Lim, J. S., Marban, P. C., Kong, L. R., Lee, Y. J., Wang, L. Z., Thuya, W. L., Soong, R., Yee, M. Q., Chin, T. M., Cordero, M. T., Asuncion, B. R., Pang, B., Pervaiz, S., Hirpara, J. L., Sinha, A., Xu, W. W., Yuasa, M., Tsunoda, T., Motoyama, M., Yamauchi, T., & Goh, B. C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 26
- Issue
- 5
- Pages
- 998-1005
- ISSN
- 0923-7534
- Cited by
- 153
- References
- 2
- Language
- en
- Licence
- Funders
- the National Medical Research Council of Singapore (NMRC/CSA/021/2010)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
